Respiratory Syncytial Virus News and Research

RSS

Promising anti-cancer agent may also prevent SARS-CoV-2 from replication

Based on findings from a new study by a Johns Hopkins Medicine-led research team, an effective means of fighting SARS-CoV-2, the virus that causes COVID-19, may be possible that circumvents the problem of waning immunity often observed when current vaccines deal with emerging COVID variants.

8 Sep 2022

COVID-19 may provoke IgA-associated vasculitis

In a new study, scientists showed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection provokes immunoglobulin A (IgA)-associated vasculitis (IgAV).

30 Aug 2022

A complex immunological landscape emerges in South Africa after Omicron BA.1/BA.2

Researchers evaluate infection rates and changes in the immunological history of COVID-19 patients over time.

25 Aug 2022

Investigation of SARS-CoV-2 and respiratory syncytial virus coinfection in children

A new study evaluated the occurrence of RSV and SARS-CoV-2 coinfections in children.

25 Aug 2022

Vaccines and monoclonal antibodies being developed for respiratory syncytial virus

A new study reviews recent advancements made in the development of RSV immunoprophylactic measures.

11 Aug 2022

Covid sewage surveillance labs join the hunt for monkeypox

The same wastewater surveillance techniques that have emerged as a critical tool in early detection of covid-19 outbreaks are being adapted for use in monitoring the startling spread of monkeypox across the San Francisco Bay Area and some other U.S. communities.

9 Aug 2022

scRNA-seq of SARS-CoV-2 infected lung organoids finds NFKB Inhibitor Alpha increased in infected cells

Researchers develop a genetically modified airway organoid system, which overcomes challenges related to natural variations in ACE2 levels

4 Aug 2022

They lost Medicaid when paperwork was sent to an empty field, signaling the mess to come

Three years ago, Mason Lester, a rambunctious toddler, tumbled off his family's porch and broke his wrist. His mother, nine months pregnant, rushed him to a nearby hospital, where she made a confounding discovery: Their health insurance had vanished.

3 Aug 2022

Pediatric adjuvant formulation offers protection against RSV in newborns

Respiratory syncytial virus (RSV) is the leading global cause of death in children under age 5 and lacks an effective vaccine. In a study from the Precision Vaccines Program at Boston Children's Hospital, a new vaccine formulation protected newborn mice against infection and evoked strong responses in immune cells from human newborns in the laboratory. Results were reported August 2 in Nature Communications.

2 Aug 2022

Study aims to assess the accuracy of influenza rapid diagnostic tests

JMIR Publications recently published "Diagnostic Accuracy of an At-Home, Rapid Self-test for Influenza: Prospective Comparative Accuracy Study" in JMIR Public Health and Surveillance which reported that rapid diagnostic tests (RDTs) for influenza used by individuals at home could potentially expand access to testing and reduce the impact of influenza on health systems.

2 Aug 2022

New AI software can create proteins that may be useful as vaccines, cancer treatments

Scientists have developed artificial intelligence software that can create proteins that may be useful as vaccines, cancer treatments, or even tools for pulling carbon pollution out of the air.

21 Jul 2022

Scientists evaluate immunostimulatory glycolipid against SARS-CoV-2 infection

A new study showed that 7DW8-5, an immunostimulatory glycolipid impeded three respiratory viral infections, including SARS-CoV-2, in vivo.

18 Jul 2022

Stinging nettle extract inhibits SARS-CoV-2 cell fusion

In a recent study posted to the bioRxiv* preprint server, researchers at Ghent University and KU Leuven, Belgium, demonstrated that Urtica dioica agglutinin (UDA), a monomeric lectin extracted from stinging nettle rhizomes, inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) cell to cell fusion.

12 Jul 2022

How Pfizer won the pandemic, reaping outsize profit and influence

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as covid-19 continues to infect tens of thousands of people and kill hundreds each day.

5 Jul 2022

The varying patterns of acute respiratory infection hospitalizations before and during two pandemic years

Investigators analyzed the varying pattern of respiratory viruses resulting in hospitalizations from 2012-2013 to 2021-2022 in Canada.

5 Jul 2022

Study looks at pneumococcal carriage among over 60's during COVID pandemic

In a recent article posted to the medRxiv* preprint server, researchers in the United States analyzed the pneumococcal carriage in older adults in the Greater New Haven Area, United States (US), during the implementation of coronavirus disease 2019 (COVID-19) mitigation strategies.

4 Jul 2022

The role of vitamin D in H1N1 influenza and SARS-CoV-2 infection

A new study focused on determining Vitamin D's role in SARS-CoV-2 and H1N1 influenza. In this study, researchers determined the effect of vitamin D supplements on the lung anti-viral response in animal models.

4 Jul 2022

COVID-19 pandemic linked to lower antibodies in breastmilk

New research describes the results of a study measuring such protection and exploring the effects of waning antibody levels on infant susceptibility to respiratory pathogens.

29 Jun 2022

Researchers identify orally efficacious antiviral drug against respiratory syncytial virus

An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could provide an effective treatment against RSV disease, according to researchers in the Center for Translational Antiviral Research at Georgia State University.

24 Jun 2022

Moderna to build large-scale mRNA manufacturing center in the UK

NHS patients will have access to the next generation of vaccines and treatments following an agreement between the government and Moderna to build a state-of-the-art manufacturing and research and development centre in the UK.

21 Jun 2022